EXOZ
eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.
eXoZymes, Inc. (EXOZ) is rated C- (2.0/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Profitability (D). The rating has held at C- for 8 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | C+ (2.5) | D+ (1.8) | D (1.3) | D+ (1.6) | C+ (2.6) | C- (2.0) |
| 2026-11-04 | C+ (2.5) | C- (1.9) | D (1.4) | C- (1.9) | C+ (2.7) | C- (2.1) |
| 2026-10-28 | C+ (2.5) | C- (1.9) | D (1.4) | D+ (1.8) | C+ (2.7) | C- (2.1) |
| 2026-10-21 | C+ (2.5) | D+ (1.8) | D (1.3) | D+ (1.7) | C+ (2.6) | C- (2.0) |
| 2026-10-14 | C+ (2.5) | D+ (1.8) | D (1.4) | D+ (1.6) | C+ (2.6) | C- (2.0) |